Graticule Appoints Patrick Wulf Hanson as Chief Alliance Officer for EU Operations
5.9.2023 17:00:00 EEST | Business Wire | Press release
Graticule, a Real World Data CRO that conducts life science research and development projects with both USA and International data partners, is pleased to announce the onboarding of Patrick Hanson as the Chief Alliance Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831939371/en/
Patrick Wulf Hanson (Photo: Business Wire)
Daniel Poscover, Founder and CEO of Graticule, mentioned, “We are thrilled to welcome Patrick to our leadership team. With his vast experience in stakeholder management, engagement, and close interactions with Key Opinion Leaders (KOLs) and regulatory authorities, I am confident that we can broaden our EU operations to a much larger network.”
Patrick has over 30 years of experience in the pharmaceutical industry, consultancy, and academia. He previously served as Vice President for Real-World Data Alliances Europe at Lumanity, Head of Real World Data Strategy Europe and Canada at Parexel, Director of Real-World Analytics & Solutions Nordics (and Head of Denmark) at IQVIA, Nordic medical director at McCann Health Nordic, Scientific Director at Cohn & Wolfe and Molecule Consultancy, and Director of Global Product Safety, Regulatory Affairs Officer, and Corporate Branding at Novo Nordisk. Before his industry work, Patrick held research and teaching positions in Sweden, Denmark, and the USA. He has also authored textbooks and peer-reviewed articles.
Patrick's vast network and diverse European experience will help introduce innovative business strategies and foster collaborations for Graticule's European operations. Patrick believes that his ability to create sustainable relationships and alliances, stakeholder engagement, communicate advanced medical content to any audience, and create value for customers and patients will help Graticule in becoming a leading player in the European market.
To learn more, visit Graticule.
About Graticule
Graticule is a Real World Data CRO that conducts life science research and development projects with both USA and International data partners. The company focuses on establishing relationships, tools, and expertise to overcome traditional barriers that have limited the applications of medical data. Graticule solutions include comparative effectiveness studies, surveillance, patient identification, clinical trial recruitment, and an automated data transfer to Electronic Data Capture systems. The company differentiates itself by focusing on timely access to relevant patient data through close engagement with both Graticule Research Network and project-specific data partners. The result of the approach is a team that can rapidly leverage advanced data sets such as clinical notes, imaging, genetic testing, and structured clinical data and can scale research to large populations over time. Our solutions include Graticule Study Source, Graticule Patient Finder, and Graticule CLEHR.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831939371/en/
Contact information
Kyle F. Conley
Vice President of People Operations, Privacy Official
kconley@graticule.life
(617) 412-0999
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Third Quarter 2026 Results3.11.2026 23:30:00 EET | Press release
IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modestly as we continue to strengthen the business. We also generated strong cash flow through the first nine months of 2026 and recently completed our $500 million accelerated share repurchase program. The separation of Food Ingredients is progressing well, and we are on track with our timelin
2026–2027 World Branding Awards Honours Global “ Brand of the Year ” Winners at Hampton Court Palace3.11.2026 22:00:00 EET | Press release
The World Branding Awards returned to honour the brands that continue to set the benchmark for excellence. The 2026–2027 World Branding Awards Ceremony took place at the iconic Hampton Court Palace, marking the 21st edition of the awards. Set within the grandeur of a historic venue, the prestigious event brought together guests from across the globe for a memorable celebration. The evening was hosted by the acclaimed BBC presenter, Hannah Gray, and was further enriched by a keynote presentation from renowned speaker Adrian Webster. Earning a World Branding Awards remains a highly distinguished achievement. Winners are determined through a rigorous evaluation process encompassing brand valuation, consumer market research, and public online voting. This year, over 105,000 consumers took part in the voting process, and more than 2,000 brands from 62 countries were nominated. Of these, less than 10 brands from each country were declared the “Brand of the Year” across the Global, Regional,
Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 20:05:00 EET | Press release
Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisition of Rosewood London reflects Gencom’s conviction in the market and serves as a strategic entry point into Europe. The transaction further enhances the firm’s assemblage
SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 17:52:00 EET | Press release
His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 17:03:00 EET | Press release
BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom